ALX raises $105M for midphase trials of CD47 cancer drug

FierceBiotech | February 12, 2020

ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies. Multiple drug developers have gone after CD47 since evidence of its role in the interactions between cancer cells and the immune system became clear. The evidence suggested tumors evade immune attacks by upregulating CD47, leading researchers to posit that blocking the signal will expose cancer cells to a full-force offensive. However, efforts to realize the therapeutic potential of anti-CD47 antibodies have been undermined by hematological adverse events stemming from the fact the target is found on host cells such as red blood cells.

Spotlight

Experiome Biotech Pvt Ltd is your destination for project dissertations, trainings, workshops, internships, thesis writing, project writing and many more biotech research and training needs.

Spotlight

Experiome Biotech Pvt Ltd is your destination for project dissertations, trainings, workshops, internships, thesis writing, project writing and many more biotech research and training needs.

Related News

MEDTECH, INDUSTRIAL IMPACT

ATUM Announces Licensing Deal with Codiak for Leap-In Transposase Technology

ATUM and Codiak | January 25, 2023

On January 24, 2023, ATUM, a global leader in bioengineering solutions, announced that it has signed a comprehensive licensing agreement with Codiak BioSciences, a clinical-stage biopharmaceutical company, for the Leap-In Transposase® technology. ATUM will grant Codiak access to its Leap-In Transposase® technology in order to create mammalian cells expressing exosomes engineered to deliver therapeutic payloads under the conditions of the agreement. The Leap-In technology is a comprehensive solution that integrates patented re-coding algorithms, unique genetic vector elements, and a transposon-based mechanism for efficiently inserting genetically stable elements into the genome. "Through years of rigorous research and clinical validation we have created a platform for engineering and manufacturing therapeutic exosomes with various payloads on the surface or inside the lumen. We believe ATUM's transposase technology has the potential to effectively synergize with Codiak's engEx® Platform to further enhance loading these vesicles, making them more potent and reducing cost of goods," Commented Scott Estes, Ph.D., VP of Cell Line Development at Codiak. (Source – Business Wire) "Exosomes are bio vesicles that have the potential to fundamentally change drug delivery. We are proud and excited to license the Leap-In Transposase® technology to Codiak for the engineering of cell lines that enables rapid and robust production of exosomes," said Claes Gustafsson, Ph.D., Chief Commercial Officer and Co-Founder at ATUM. (Source – Business Wire) About Codiak Founded in 2015, Codiak is a clinical-stage biopharmaceutical firm focused on developing exosome-based treatments, a new class of medications with the potential to change the treatment of a variety of diseases with high unmet medical needs. It created a proprietary engEx Platform that uses exosome biology as natural intercellular transfer mechanisms to design, construct, and manufacture innovative exosome therapeutic candidates. By utilizing its engEx Platform, it has produced a rich pipeline of engineered exosomes for neuro-oncology, oncology, neurology, neuromuscular, and infectious diseases.

Read More

INDUSTRIAL IMPACT, DIAGNOSTICS

AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease

businesswire | March 23, 2023

AbCellera and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV). The partnership aims to provide long-lasting infectious diseases medicines to high-risk patients by bringing together RQ Bio’s expertise in infectious diseases and viral evolution with AbCellera’s discovery engine for finding rare, highly potent antibodies. “We believe antibody therapies have an important role to play in protecting the most clinically at-risk populations from infectious diseases,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “AbCellera’s discovery engine complements RQ Bio’s capabilities and provides a technology advantage that we believe will help bring new medicines for infectious disease to patients faster.” “Both RQ Bio and AbCellera have proven track records in developing infectious disease medicines that have a rapid impact on vulnerable patients,” said Hugo Fry, CEO of RQ Bio. “We look forward to working with AbCellera to quickly advance our pipeline of infectious disease medicines for people who are at risk of severe disease or death from viral infections.” Under the terms of the agreement, RQ Bio has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive downstream clinical and regulatory milestone payments and royalties on net sales of products. About AbCellera Biologics Inc. AbCellera is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner. AbCellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development.

Read More

MEDTECH, INDUSTRIAL IMPACT

Synergy Oncology to use SOPHiA DDM for New Cancer Profiling Solution

SOPHiA GENETICS | March 01, 2023

On February 28, 2023, SOPHiA GENETICS, a leading cloud-native software solutions provider in the healthcare space, announced that Synergy Oncology, a part of Synergy Laboratories based in Mobile, Alabama, will utilize SOPHiA DDM™ to develop a new cancer profiling solution. Synergy Oncology is a specialist in innovative platforms that improve patient care. The use of SOPHiA DDM™ for Hereditary Cancers Solution in Synergy Oncology's state-of-the-art laboratory technologies will lead to the launch of Totality, a comprehensive end-to-end solution for tumor profiling that will assist clinical studies, cancer research and patient care. Next-generation sequencing (NGS) is commonly used to detect biomarkers for hereditary cancers, but the resulting datasets are vast and complex, requiring sophisticated analysis. The SOPHiA DDM™ for Hereditary Cancers Solution leverages machine learning and Artificial Intelligence (AI) with patented technologies to evaluate raw NGS data, simplifying interpretation and expediting reporting. As Synergy Laboratories seeks to expand into other oncology offerings, the SOPHiA DDM™ platform could serve as a one-stop solution. Synergy's new product, Totality, examines genes from solid tumor tissue and, by using SOPHiA DDM™ for Hereditary Cancers, provides physicians with a consolidated report that matches detected molecular alterations with clinical trials and FDA-approved therapies. By combining SOPHiA DDM™ for Hereditary Cancers with Synergy Oncology's technology, experts will be able to analyze and interpret findings from NGS data confidently, transforming high-quality data into valuable insights for researchers and care providers. Synergy Oncology provides the most comprehensive NGS kit of its kind, including hereditary testing, liquid biopsy testing, and myeloid malignancies. The combination of Synergy Oncology and SOPHiA GENETICS technology will expand Synergy's oncology portfolio while helping to further the U.S. oncology market. About SOPHiA GENETICS SOPHiA GENETICS is a leading cloud-native software solutions provider in the healthcare space. It aims to establish data-driven medicine as the standard of care for life sciences research. The company combines expertise in life sciences, data computing and medical disciplines to bring data analytics solutions to market. SOPHiA GENETICS achieve its mission through the global adoption of SOPHiA AI, which uses pattern recognition, statistical inference and machine learning to provide equal benefits to all users. SOPHiA AI also encourages expert knowledge sharing for a sustainable impact on future patients. The company believes digital technologies are the key to unlocking the era of Data-Driven Medicine, where secure data pooling and knowledge sharing will be precious for patients. The company also focuses on combining the first two pillars of Data-Driven Medicine, Radiomics and Genomics, to ensure that the data used to help patients today will also benefit tomorrow's patients.

Read More